You are here: Industry Insights > Rinvoq

News List

NICE backs AbbVie’s Rinvoq for severe active rheumatoid arthritis pharmatimes
November 09, 2020
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Rinvoq (upadacitinib) for people with previously treated severe active rheumatoid arthritis (RA).
AbbVie Submits Regulatory Application to FDA for Rinvoq for Ankylosing Spondylitis americanpharmaceuticalreview
August 26, 2020
AbbVie has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for Rinvoq™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with ...
Study Shows RINVOQ, Topical Corticosteroids Improves Atopic Dermatitis Symptoms americanpharmaceuticalreview
August 04, 2020
AbbVie announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of RINVOQ in atopic dermatitis.
AbbVie's Rinvoq hits targets in atopic dermatitis trial pharmatimes
July 23, 2020
AbbVie's Rinvoq (upadacitinib) monotherapy has hit both primary and secondary targets in the Measure Up 2 trial, the second Phase III study in individuals with moderate to severe atopic dermatitis.
AbbVie's Rinvoq shows potential for atopic dermatitis pharmatimes
June 22, 2020
AbbVie has presented new data showing that Rinvoq (upadacitinib) monotherapy induced significant improvements in skin clearance in people with atopic dermatitis.
AbbVie Submits Regulatory Applications to FDA, EMA for Psoriatic Arthritis Treatment americanpharmaceuticalreview
June 15, 2020
AbbVie has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for RINVOQ™ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor ...
AbbVie files Rinvoq for psoriatic arthritis pharmatimes
June 04, 2020
AbbVie is seeking to expand the scope of Rinvoq (upadacitinib) in the US and Europe to include the treatment of adults with active psoriatic arthritis.
AbbVie Receives EC Approval of RINVOQ for Rheumatoid Arthritis americanpharmaceuticalreview
December 19, 2019
AbbVie announced the European Commission (EC) has approved RINVOQ™ (upadacitinib) for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have ...
AbbVie receives FDA approval for RINVOQ biospectrumasia
August 20, 2019
RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis
RINVOQ™ arthritis treatment granted approval by FDA europeanpharmaceuticalreview
August 20, 2019
The FDA has given its approval to RINVOQ for the treatment of active rheumatoid arthritis after the drug reached its endpoints in clinical trials.

Previous page 1 2 3 Next page